The lysophosphatidylinositol receptor GPR55 modulates pain perception in the periaqueductal gray

Molecular Pharmacology

Volumn 88, Issue 2, 2015, Pages 265-272

  Deliu, Elena ^a   Sperow, Margaret ^a   Console Bram, Linda ^a   Carter, Rhonda L ^a   Tilley, Douglas G ^a   Kalamarides, Daniel J ^a   Kirby, Lynn G ^a   Brailoiu, G Cristina ^b   Brailoiu, Eugen ^a   Benamar, Khalid ^a,c   Abood, Mary E ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CANNABINOID RECEPTOR; GPR55 PROTEIN, MOUSE; LYSOPHOSPHATIDYLINOSITOL; LYSOPHOSPHOLIPID;

ANIMAL; CELL CULTURE; DRUG EFFECTS; FEMALE; GENETICS; MALE; MEMBRANE POTENTIAL; METABOLISM; NERVE CELL; NEWBORN; NOCICEPTION; PERIAQUEDUCTAL GRAY MATTER; PHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; ANIMALS, NEWBORN; CALCIUM; CELLS, CULTURED; FEMALE; LYSOPHOSPHOLIPIDS; MALE; MEMBRANE POTENTIALS; NEURONS; PAIN PERCEPTION; PERIAQUEDUCTAL GRAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CANNABINOID;

EID: 84939792041     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.115.099333     Document Type: Article

References (42)

1. Basbaum AI and Fields HL (1984) Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci 7:309-338.
2. Benamar K, Geller EB, and Adler MW (2008a) First in vivo evidence for a functional interaction between chemokine and cannabinoid systems in the brain. J Pharmacol Exp Ther 325:641-645.
3. Benamar K, Geller EB, and Adler MW (2008b) A new brain area affected by 3,4-methylenedioxymethamphetamine: A microdialysis-biotelemetry study. Eur J Pharmacol 596:84-88.
4. Bilmen JG and Michelangeli F (2002) Inhibition of the type 1 inositol 1,4,5-trisphosphate receptor by 2-aminoethoxydiphenylborate. Cell Signal 14:955-960.
5. Brailoiu GC, Deliu E, Hooper R, Dun NJ, Undieh AS, Adler MW, Benamar K, and Brailoiu E (2012) Agonist-selective effects of opioid receptor ligands on cytosolic calcium concentration in rat striatal neurons. Drug Alcohol Depend 123:277-281.
6. Caggiula AR, Epstein LH, Perkins KA, and Saylor S (1995) Different methods of assessing nicotine-induced antinociception may engage different neural mechanisms. Psychopharmacology (Berl) 122:301-306.
7. Chen X, Kirby LG, Palma J, Benamar K, Geller EB, Eisenstein TK, and Adler MW (2011) The effect of gp120 on morphine's antinociceptive and neurophysiological actions. Brain Behav Immun 25:1434-1443.
8. Connor M and Christie MJ (1998) Modulation of Ca2+ channel currents of acutely dissociated rat periaqueductal grey neurons. J Physiol 509:47-58.
9. Deliu E, Brailoiu GC, Arterburn JB, Oprea TI, Benamar K, Dun NJ, and Brailoiu E (2012) Mechanisms of G protein-coupled estrogen receptor-mediated spinal nociception. J Pain 13:742-754.
10. Deliu E, Brailoiu GC, Eguchi S, Hoffman NE, Rabinowitz JE, Tilley DG, Madesh M, Koch WJ, and Brailoiu E (2014) Direct evidence of intracrine angiotensin II signaling in neurons. Am J Physiol Cell Physiol 306:C736-C744.
11. Falasca M, Silletta MG, Carvelli A, Di Francesco AL, Fusco A, Ramakrishna V, and Corda D (1995) Signalling pathways involved in the mitogenic action of lysophosphatidylinositol. Oncogene 10:2113-2124.
12. Gafni J, Munsch JA, Lam TH, Catlin MC, Costa LG, Molinski TF, and Pessah IN (1997) Xestospongins: potent membrane permeable blockers of the inositol 1,4,5-trisphosphate receptor. Neuron 19:723-733.
13. Gangadharan V, Selvaraj D, Kurejova M, Njoo C, Gritsch S, Škoricová D, Horstmann H, Offermanns S, Brown AJ, and Kuner T et al. (2013) A novel biological role for the phospholipid lysophosphatidylinositol in nociceptive sensitization via activation of diverse G-protein signalling pathways in sensory nerves in vivo. Pain 154:2801-2812.
14. Heinisch S and Kirby LG (2010) SDF-1alpha/CXCL12 enhances GABA and glutamate synaptic activity at serotonin neurons in the rat dorsal raphe nucleus. Neuropharmacology 58:501-514.
15. Heinricher MM, Tavares I, Leith JL, and Lumb BM (2009) Descending control of nociception: Specificity, recruitment and plasticity. Brain Res Brain Res Rev 60:214-225.
16. Henstridge CM (2012) Off-target cannabinoid effects mediated by GPR55. Pharmacology 89:179-187.
17. Henstridge CM, Balenga NA, Kargl J, Andradas C, Brown AJ, Irving A, Sanchez C, and Waldhoer M (2011) Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55. Mol Endocrinol 25:1835-1848.
18. Heynen-Genel S, Dahl R, Shi S, Milan L, Hariharan S, Sergienko E, Hedrick M, Dad S, Stonich D, Su Y, et al. (2010) Screening for selective ligands for GPR55 - Antagonists. Probe Reports from the NIH Molecular Libraries Program. National Center for Biotechnology Information, Bethesda, MD; 2010 Oct 30 [updated 2011 May 26].
19. Kapur A, Zhao P, Sharir H, Bai Y, Caron MG, Barak LS, and Abood ME (2009) Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem 284:29817-29827.
20. Knight YE, Bartsch T, and Goadsby PJ (2003) Trigeminal antinociception induced by bicuculline in the periaqueductal gray (PAG) is not affected by PAG P/Q-type calcium channel blockade in rat. Neurosci Lett 336:113-116.
21. Knight YE, Bartsch T, Kaube H, and Goadsby PJ (2002) P/Q-type calcium-channel blockade in the periaqueductal gray facilitates trigeminal nociception: a functional genetic link for migraine? J Neurosci 22:1-6.
22. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, and Mackie K (2008) GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci USA 105:2699-2704.
23. Ma MT, Yeo JF, Shui G, Wenk MR, and Ong WY (2012) Systems wide analyses of lipids in the brainstem during inflammatory orofacial pain - evidence of increased phospholipase A(2) activity. Eur J Pain 16:38-48.
24. Maruyama T, Kanaji T, Nakade S, Kanno T, and Mikoshiba K (1997) 2APB, 2-aminoethoxydiphenyl borate, a membrane-penetrable modulator of Ins(1,4,5)P3-induced Ca2+ release. J Biochem 122:498-505.
25. Naylor E, Arredouani A, Vasudevan SR, Lewis AM, Parkesh R, Mizote A, Rosen D, Thomas JM, Izumi M, and Ganesan A et al. (2009) Identification of a chemical probe for NAADP by virtual screening. Nat Chem Biol 5:220-226.
26. Park C, Kim JH, Yoon BE, Choi EJ, Lee CJ, and Shin HS (2010) T-type channels control the opioidergic descending analgesia at the low threshold-spiking GABAergic neurons in the periaqueductal gray. Proc Natl Acad Sci USA 107:14857-14862.
27. Paxinos G and Watson C (1988) The rat brain in stereotaxic coordinates, Academic Press, San Diego.
28. Piñeiro R and Falasca M (2012) Lysophosphatidylinositol signalling: new wine from an old bottle. Biochim Biophys Acta 1821:694-705.
29. Porreca F, Ossipov MH, and Gebhart GF (2002) Chronic pain and medullary descending facilitation. Trends Neurosci 25:319-325.
30. Rizzuto R and Pozzan T (2006) Microdomains of intracellular Ca2+: molecular determinants and functional consequences. Physiol Rev 86:369-408.
31. Ross RA (2011) L-α-lysophosphatidylinositol meets GPR55: a deadly relationship. Trends Pharmacol Sci 32:265-269.
32. Rubinstein M, Mogil JS, Japón M, Chan EC, Allen RG, and Low MJ (1996) Absence of opioid stress-induced analgesia in mice lacking beta-endorphin by site-directed mutagenesis. Proc Natl Acad Sci USA 93:3995-4000.
33. Shen Z, Wu M, Elson P, Kennedy AW, Belinson J, Casey G, and Xu Y (2001) Fatty acid composition of lysophosphatidic acid and lysophosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases. Gynecol Oncol 83:25-30.
34. Staton PC, Hatcher JP, Walker DJ, Morrison AD, Shapland EM, Hughes JP, Chong E, Mander PK, Green PJ, and Billinton A et al. (2008) The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 139:225-236.
35. Sutphen R, Xu Y, Wilbanks GD, Fiorica J, Grendys EC, Jr, LaPolla JP, Arango H, Hoffman MS, Martino M, and Wakeley K et al. (2004) Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev 13:1185-1191.
36. Vaughan CW and Christie MJ (1997) Presynaptic inhibitory action of opioids on synaptic transmission in the rat periaqueductal grey in vitro. J Physiol 498:463-472.
37. Vaughan CW, Connor M, Bagley EE, and Christie MJ (2000) Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol Pharmacol 57:288-295.
38. Vaughan CW, Ingram SL, and Christie MJ (1997) Actions of the ORL1 receptor ligand nociceptin on membrane properties of rat periaqueductal gray neurons in vitro. J Neurosci 17:996-1003.
39. Wu CS, Chen H, Sun H, Zhu J, Jew CP, Wager-Miller J, Straiker A, Spencer C, Bradshaw H, and Mackie K et al. (2013) GPR55, a G-protein coupled receptor for lysophosphatidylinositol, plays a role in motor coordination. PLoS ONE 8:e60314.
40. Xiao YJ, Schwartz B, Washington M, Kennedy A, Webster K, Belinson J, and Xu Y (2001) Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal Biochem 290:302-313.
41. Yeo JF, Ong WY, Ling SF, and Farooqui AA (2004) Intracerebroventricular injection of phospholipases A2 inhibitors modulates allodynia after facial carrageenan injection in mice. Pain 112:148-155.
42. Yu J, Deliu E, Zhang XQ, Hoffman NE, Carter RL, Grisanti LA, Brailoiu GC, Madesh M, Cheung JY, and Force T et al. (2013) Differential activation of cultured neonatal cardiomyocytes by plasmalemmal versus intracellular G protein-coupled receptor 55. J Biol Chem 288:22481-22492.